Paolo A Ascierto


Ontology type: schema:Person     


Person Info

NAME

Paolo A

SURNAME

Ascierto

Publications in SciGraph latest 50 shown

  • 2018-12 Inhibition of Stearoyl-CoA desaturase 1 reverts BRAF and MEK inhibition-induced selection of cancer stem cells in BRAF-mutated melanoma in JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
  • 2018-12 The influence of diet on anti-cancer immune responsiveness in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2018-12 Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November–2 December, 2017, Naples, Italy) in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2018-12 The Great Debate at “Melanoma Bridge”, Napoli, December 2nd, 2017 in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2018-12 Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy) in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2018-12 Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2018-09-25 Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanoma in CELL DEATH & DIFFERENTIATION
  • 2018-03-20 Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation–positive melanoma in BRITISH JOURNAL OF CANCER
  • 2018 Side Effects of Cancer Immunotherapy with Checkpoint Inhibitors in ONCOIMMUNOLOGY
  • 2017-12 The need for a network to establish and validate predictive biomarkers in cancer immunotherapy in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2017-12 World-Wide Immunoscore Task Force: meeting report from the “Melanoma Bridge”, Napoli, November 30th–December 3rd, 2016 in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2017-12 Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future? in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2017-12 Genetic instability and increased mutational load: which diagnostic tool best direct patients with cancer to immunotherapy? in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2017-12 Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2017-12 Electrochemotherapy efficacy evaluation for treatment of locally advanced stage III cutaneous squamous cell carcinoma: a 22-cases retrospective analysis in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2017-12 Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge”, Napoli, November 30th 2016 in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2017-12 MEK Inhibitors in the Treatment of Metastatic Melanoma and Solid Tumors in AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
  • 2017-12 COX-2 expression positively correlates with PD-L1 expression in human melanoma cells in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2017-12 Future perspectives in melanoma research “Melanoma Bridge”, Napoli, November 30th–3rd December 2016 in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2017-12 Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2017-12 Targeting the cross-talk between Urokinase receptor and Formyl peptide receptor type 1 to prevent invasion and trans-endothelial migration of melanoma cells in JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
  • 2017-09 FKBP51s signature in peripheral blood mononuclear cells of melanoma patients as a possible predictive factor for immunotherapy in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2017-02 Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care in BIODRUGS
  • 2017-01 Immunotherapy Bridge 2016 and Melanoma Bridge 2016: meeting abstracts in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2016-12 The 2nd meeting of the Campania Society of Oncology Immunotherapy (SCITO): focus on hepatocellular carcinoma, kidney and bladder cancer in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2016-12 Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge”, Napoli, December 5th 2015 in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2016-12 Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2016-12 Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015 in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2016-12 What have we learned from immunotherapy? Report from the 3rd and 4th meetings of the Campania Society of Oncology Immunotherapy (SCITO) in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2016-12 Future perspectives in melanoma research in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2016-11 Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series in BRITISH JOURNAL OF CANCER
  • 2016-11 Complete response to nivolumab monotherapy in a treatment-naive, BRAF wild-type patient with advanced mucosal melanoma and elevated lactate dehydrogenase: a case report from a phase III trial in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2016-11 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2016-09 Systematic review of the use of granulocyte–macrophage colony-stimulating factor in patients with advanced melanoma in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2016-07 Melanoma and immunotherapy bridge 2015 in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2016-06 Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection? in DRUGS
  • 2015-12 Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032 in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2015-12 What’s new in melanoma? Combination! in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2015-12 Analysis of T and NK cells immune response in Ipilimumab treated Melanoma patients in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2015-12 Future perspectives in melanoma research: meeting report from the “Melanoma Bridge”: Napoli, December 3rd–6th 2014 in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2015-12 AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2015-12 Correlation between BRAF mutational status and clinical response to pembrolizumab in advanced melanoma patients in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2015-12 Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2015-12 coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAFV600 mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519) in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2015-12 Dendritic cell-derived exosomes (Dex) are potential biomarkers of response to Ipilimumab in metastatic melanoma in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2015-12 The immune-related role of BRAF in melanoma in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2015-12 Correlation between immune-related adverse events and response to pembrolizumab in advanced melanoma patients in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2015-12 A Phase III study (CheckMate 238) of adjuvant immunotherapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage IIIb/c or stage IV melanoma (MEL) in patients (pts) at high risk for recurrence in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2015-12 ErbB3 plays a key role in the early phase of establishment of resistance to BRAF and/or MEK inhibitors in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2015-12 A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma in JOURNAL OF TRANSLATIONAL MEDICINE
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "affiliation": [
          {
            "affiliation": {
              "id": "https://www.grid.ac/institutes/grid.417893.0", 
              "type": "Organization"
            }, 
            "isCurrent": true, 
            "type": "OrganizationRole"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.266539.d", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.257413.6", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.484420.e", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.48336.3a", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.419457.a", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.5606.5", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.10306.34", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.240145.6", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.476273.3", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.25879.31", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.11450.31", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.419690.3", 
            "type": "Organization"
          }
        ], 
        "familyName": "Ascierto", 
        "givenName": "Paolo A", 
        "id": "sg:person.01212502023.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01212502023.44"
        ], 
        "sdDataset": "persons", 
        "sdDatePublished": "2019-03-07T14:54", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-uberresearch-data-dimensions-researchers-20181010/20181011/dim_researchers/base/researchers_621.json", 
        "type": "Person"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/person.01212502023.44'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/person.01212502023.44'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/person.01212502023.44'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/person.01212502023.44'


     

    This table displays all metadata directly associated to this object as RDF triples.

    40 TRIPLES      10 PREDICATES      23 URIs      7 LITERALS      2 BLANK NODES

    Subject Predicate Object
    1 sg:person.01212502023.44 schema:affiliation N8a1244ac07904323a94939cd2addd4f3
    2 https://www.grid.ac/institutes/grid.10306.34
    3 https://www.grid.ac/institutes/grid.11450.31
    4 https://www.grid.ac/institutes/grid.240145.6
    5 https://www.grid.ac/institutes/grid.257413.6
    6 https://www.grid.ac/institutes/grid.25879.31
    7 https://www.grid.ac/institutes/grid.266539.d
    8 https://www.grid.ac/institutes/grid.419457.a
    9 https://www.grid.ac/institutes/grid.419690.3
    10 https://www.grid.ac/institutes/grid.476273.3
    11 https://www.grid.ac/institutes/grid.48336.3a
    12 https://www.grid.ac/institutes/grid.484420.e
    13 https://www.grid.ac/institutes/grid.5606.5
    14 schema:familyName Ascierto
    15 schema:givenName Paolo A
    16 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01212502023.44
    17 schema:sdDatePublished 2019-03-07T14:54
    18 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    19 schema:sdPublisher N9c3e446ed673494e930ecff2ea5e19fe
    20 sgo:license sg:explorer/license/
    21 sgo:sdDataset persons
    22 rdf:type schema:Person
    23 N8a1244ac07904323a94939cd2addd4f3 schema:affiliation https://www.grid.ac/institutes/grid.417893.0
    24 sgo:isCurrent true
    25 rdf:type schema:OrganizationRole
    26 N9c3e446ed673494e930ecff2ea5e19fe schema:name Springer Nature - SN SciGraph project
    27 rdf:type schema:Organization
    28 https://www.grid.ac/institutes/grid.10306.34 schema:Organization
    29 https://www.grid.ac/institutes/grid.11450.31 schema:Organization
    30 https://www.grid.ac/institutes/grid.240145.6 schema:Organization
    31 https://www.grid.ac/institutes/grid.257413.6 schema:Organization
    32 https://www.grid.ac/institutes/grid.25879.31 schema:Organization
    33 https://www.grid.ac/institutes/grid.266539.d schema:Organization
    34 https://www.grid.ac/institutes/grid.417893.0 schema:Organization
    35 https://www.grid.ac/institutes/grid.419457.a schema:Organization
    36 https://www.grid.ac/institutes/grid.419690.3 schema:Organization
    37 https://www.grid.ac/institutes/grid.476273.3 schema:Organization
    38 https://www.grid.ac/institutes/grid.48336.3a schema:Organization
    39 https://www.grid.ac/institutes/grid.484420.e schema:Organization
    40 https://www.grid.ac/institutes/grid.5606.5 schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...